Biogen Idec - Products on the Market home | contact info | locations | site map investor relations | careers Company Products - Products on the Market - Product Development - Science - Manufacturing Patients Products on the Market TYSABRI® (natalizumab) Please click here for the Dear Healthcare Professional Letter Regarding TYSABRI®.
Advances in the Treatment of Cardiovascular Diseases Pg 179A:1112-85) Coronary Artery Disease Bivalirudin (Angiomax ®, The Medicines Company) In a single center series of patients undergoing percutaneous coronary intervention with the direct thrombin inhibitor bivalirudin, there was a significant reduction of adverse ischemic and hemorrhagic events and glycoprotein IIb/IIIa inhibitor usage compared to present...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
Advances in the Treatment of Cardiovascular Diseases Pg 179A:1112-85) Coronary Artery Disease Bivalirudin (Angiomax ®, The Medicines Company) In a single center series of patients undergoing percutaneous coronary intervention with the direct thrombin inhibitor bivalirudin, there was a significant reduction of adverse ischemic and hemorrhagic events and glycoprotein IIb/IIIa inhibitor usage compared to present...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
PDF cover 0445.qxd DOLPHIN Current Patents Gazette Patenting in Context News & Highlights from Week 0445 The records appearing in this Gazette will be added to DOLPHIN, the database Of all pharmaceutical inventions in the next week.
author: LEmson
Gazette Highlights News 2004 - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - Thomson Scientific : Gazette Weekly Highlights News : Gazette Highlights News 2004 - Gazette Highlights News 2004 Click on a week to view more Week 53: Wednesday December 29th saw publication of 2,284 new PCT applications by WIPO, the output for “Week 53” of 2004.
Btech News - Benefits of Angiomax and Refludan - - - - BioNews BioWeb Companies Products BioReports - - - - - - Btech News - Benefits of Angiomax and Refludan Bivalent direct thrombin inhibitors (The Medicines Company's [NASDAQ: MDCO] Angiomax [bivalirudin] and Aventis's (NYSE: AVE) Refludan [lepirudin]) demonstrated important clinical advantages over univalent direct thrombin inhibitors (GlaxoSmithKline [NYSE:...
Meta-Analysis Demonstrates Angiomax Benefit for Patients with Renal Impairment A presentation at the American College of Cardiology meeting solidifies The Medicines Company’s (NASDAQ: MDCO) Angiomax (bivalirudin) as a consideration for use in renally impaired patients undergoing percutaneous coronary interventions (PCI).Angiomax risk reduction for patients stratified by renal function, the...
Approved Products_2004.xls Of E pivir, Retrovir, Ziagen HIV infection BioChem Pharma LIST OF APPROVED BIOTECHNOLOBY PRODUCTS (Page 4: product 151- 200) Number Approval Date Trade Name Generic/ Chemical name Indication Company 151 Dec- 00 Angiomax Bivalirudin Unstable Angina The Medicines Company 152 Dec- 00 Tamiflu Oseltamivir phosphate Liquid suspension for children ages 1- 12 Gilead Sciences 153...
author: Reijer
Approved Products_2004.xls page 4
author: Reijer
The Medicines Company (MDCO) Phase IIIb/IV - Working closely with both the endovascular and surgical teams to: Identify, recruit and develop sites for clinical trials of Angiomax and other products.Angiomax or other products.
The Medicines Company (MDCO) -------- Meeting the demands of the world's most advanced medical practitioners - The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care.Angiomax ® (bivalirudin), an anticoagulant approved in the U.S.
http://www.themedicinescompany.com/%7Eproducts_content/PN1002-6.pdf DESCRIPTION Angiomax ® (bivalirudin) is a specific and reversible direct thrombin inhibitor.Angiomax ® (bivalirudin) and heparin treatment groups (about 20% in both groups).Angiomax in clinical trials and were tested for...
http://www.themedicinescompany.com/%7Eproducts_content/PN1002-6.pdf page 2
duplicates:http://www.themedicinescompany.com/PN1601-7%20mc3.pdf
http://www.themedicinescompany.com/%7Eproducts_content/PN1002-6.pdf page 1
duplicates:http://www.themedicinescompany.com/PN1601-7%20mc3.pdf
http://www.themedicinescompany.com/PN1601-7%20mc3.pdf DESCRIPTION Angiomax ® (bivalirudin) is a specific and reversible direct thrombin inhibitor.Angiomax ® (bivalirudin) and heparin treatment groups (about 20% in both groups).Angiomax in clinical trials and were tested for...
The Medicines Company (MDCO) Product Overview Angiomax ® (bivalirudin) is an anticoagulant currently approved in the US and other countries for use in patients undergoing coronary angioplasty procedures.Angiomax is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous translumenal coronary...
Highlighted Poster Sessions at ACC 2005 Addo 1039-25/25 Bivalirudin Versus Heparin in Percutaneous Coronary Interventions: A Meta-Analysis, Ramin Ebrahimi Monday, March 7, 2005, 2:30-3:30 pm Hall E1, Orange County Convention Center 1093-17 Angiomax ® (bivalirudin) Versus Heparin as an Antithrombotic Agent in Patients Treated with Sirolimus-Eluting Stents, Seung-Woon Rha Tuesday, March 8, 2005, 1:30-2...
Highlighted Presentations at ACC 2005 March 6-9, 2005 Orange County Convention Center, Orlando, FL Register Online for Cocktail Reception and Evening Symposium* Highlighted Poster Sessions Angiomax ® (bivalirudin) Package Insert Faculty will present new clinical trial data at ACC 2005: Data on anemia and its impact on mortality New data from the STENT registry comparing safety and efficacy of ...
Highlighted Symposium at ACC 2005 This event is not part of the official ACC Annual Scientific Session as planned by the Annual Scientific Session Program Committee ( ASSPC).Angiomax ® (bivalirudin) Package Insert www.themedicinescompany.com - Highlighted Presentations Highlighted Symposium Highlighted Poster Sessions Online Registration...
Online Registration for Symposium at ACC 2005 Online Registration Pharmacologic Efficacy in Interventions: Contributions of Ischemia and Bleeding Saturday, March 5, 2005 7:00 - 9:00 p.m.
Database A A - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
Database B B - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
The Medicines Company (MDCO) Product Overview Clevelox™ (clevidipine) is an investigational agent undergoing late-stage clinical development to evaluate its potential as an innovative, targeted, fast acting intravenous product under investigation for lowering blood pressure before, during and after surgery.
The Medicines Company (MDCO) Programs The Medicines Company is conducting several development programs with planned and executed clinical trials.
The Medicines Company (MDCO) Specialty Pharmaceuticals The Medicines Company's business is focused on acquiring, developing, and commercializing specialty pharmaceutical products discovered by pharmaceutical and biotechnology companies.
